By Josh White
Date: Wednesday 15 Jul 2026
(Sharecast News) - Johnson & Johnson raised its full-year outlook on Wednesday after second-quarter sales rose 6.6% to $25.31bn, ahead of market expectations, while adjusted earnings increased 4.7% to $2.90 per share.
| Johnson & Johnson agrees to pay £13bn for Switze... | 28-Apr-2011 | The Independent |
| S&N DRIFTS AS BID HOPES SLIP | 19-Apr-2011 | Express & Star |
| J&J asks judge to dismiss kickback case | 08-Oct-2010 | Wall Street Journal |
| Genzyme Again Rejects Sanofi’s Bid | 08-Oct-2010 | New York Times |
| Johnson & Johnson buying vaccine maker Crucell | 07-Oct-2010 | USA Today |
| Currency | US Dollars |
| Share Price | $ 269.99 |
| Change Today | $ -0.23 |
| % Change | -0.09 % |
| 52 Week High | $278.43 |
| 52 Week Low | $174.16 |
| Volume | 16,428,384 |
| Shares Issued | 2,407.94m |
| Market Cap | $650,120m |
| RiskGrade | 87 |
| Strong Buy | 8 |
| Buy | 8 |
| Neutral | 8 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 24 |

| Time | Volume / Share Price |
| 16:00 | 8,343,978 @ $269.99 |
| 15:59 | 100 @ $269.98 |
| 15:59 | 3,305 @ $269.98 |
| 15:59 | 100 @ $269.98 |
| 15:59 | 700 @ $269.98 |
You are here: research